

#### REPORT ON SALARIES AND OTHER REMUNERATION TO LEADING PERSONNEL IN NAVAMEDIC ASA 2022

#### Introduction

This report on salaries and other remuneration to leading personnel (the "**Report**") of Navamedic ASA (the "**Company**") is based on the guidelines for the determination of salaries and other remuneration of leading personnel in the Company which were approved by the Company's general meeting on 03.06.2021 ("**Guidelines**").

The report is based on the requirements set out in the Norwegian Public Limited Companies Act of 13 June 1997 no. 45 (the "**Companies Act**") section 6-16 a and 6-16 b, as well as Regulation on guidelines and report on remuneration for leading personnel of 11 December 2021 No. 2730 (the "**Regulation**"). The report is formulated in line with the European Commission's template for remuneration reports.<sup>1</sup>

Remuneration to board members is not covered by this Report. Any remuneration to board members is determined by the general meeting in accordance with the Companies Act section § 6-10 and is available in note 17 in the consolidated financial accounts in the annual report for 2022.

## **Company performance**

#### The company performance in 2022

2022 was a year with significant performance improvements over the previous year. The revenue growth for the Company was 37.2%, driven in particular by products/product groups: Mysimba and the antibiotics portfolio. The gross margin also showed improvements, from 40.1% in 2021 to 42.8% in 2022. The improvement in gross margin was mostly due to favourable product mix as well as cost improvement initiatives. The EBITDA for 2022 improved significantly from 18.2MNOK in 2021 to EBITDA of 51.7MNOK in 2022. See also the 2022 Navamedic ASA annual report for more details on the 2022 company performance.

# The guidelines for remuneration that the Company adopted in 2021

Navamedic ASAs guidelines on the determination of salaries and other remuneration for executive personnel were approved at the company's Annual General Meeting in 2021. The guidelines are summarised below:

#### Introduction

The main principle for Navamedic's remuneration policy is that the Senior Executives shall be offered competitive terms when their total remuneration package is taken into account. Such package may consist of elements such as base salary, performance-based bonus, option programs, benefits in kind and pension arrangements. Navamedic shall seek to offer a remuneration level that is considered competitive and on market terms, compared to the level offered by similar small pharmaceutical companies in the Nordic region, and which contribute to satisfy the Group's need to recruit and keep highly qualified personnel.

# Fixed remuneration

The fixed remuneration provided to Senior Executives includes a base salary and benefits in kind such as a car allowance, mileage agreements and telephone. The Senior Executives also have insurance coverage and other benefits in line with what is offered to the other employees in accordance with collective agreements, legislation and normal practice in Norwegian companies.

#### Variable remuneration

In order to implement and achieve Navamedic's business strategy, long-term interests and financial sustainability, the executive personnel may receive variable remuneration in the form of performance-based bonus. Such performance-based bonus shall be agreed on an individual basis if applicable. The criteria for any performance-based bonus shall be determined by the board of directors and shall be linked to measurable factors, such as the achievement of pre-determined KPIs.

The Company aims to increase its revenues and strengthen its profitability. The Company's key drivers for growth are to deliver growth on existing product portfolio as well as winning new distribution agreements and/or market authorizations for new products. This is reflected in the KPIs to the executive personnel.

#### Option program

In order to further align the interests of the Senior Executives by those of the Company, share options in the Company may be granted to the senior executives as a part of their total remuneration package. Such alignment of interests is considered important to fulfil the Company's goals.

#### Remuneration to executive personnel

#### Executive personnel as at the date of this report

As of the date of this report, the following persons are considered executive personnel:

- CEO Kathrine Gamborg Andreassen
- CFO Lars Hjarrand

#### Remuneration composition

The fixed remuneration will constitute the main component of the Senior Executives' total remuneration. The fixed remuneration for the Senior Executives consists of several different items. The base salary shall be determined based on job level, local competition, market salary for similar positions and performance level. The fixed salary may be adjusted annually. Senior Executives may also be offered additional contribution in the form of free newspaper, coverage of phone/phone expenses, internet services and car allowance/company car. Furthermore, Senior Executives participate in the Company's insurance scheme as well as in the Company's defined contribution pension scheme, which currently is 5.5% of salary from OG to 7.1G and 15% from 7.1G to 12G.

Further, the Company has a variable remuneration scheme. The Company has a performance-based bonus scheme for the Senior Executives, which is based on the Group's results as well as individual KPIs. The individual KPIs are agreed specifically for each role to the extent possible, and all KPIs are set to underpin the Company's strategy. To determine if the goals have been met, a quantitative assessment is made of the quantitative goals, while individual assessments are made for the qualitative goals. As a general guideline, the performance-based bonus for the CEO should be linked to the completion of growth initiatives such as building a pipeline of innovative products as well as acquisitions of marketing authorizations and/or product portfolios. The performance-based bonus for the CFO should be linked to the satisfactorily completion of projects and initiatives tied to completion of new product acquisition, increased margins as well as cost control.

Table 1. The table below shows total remuneration the Company's executive personnel for the years 2021 and 2022

Name of		Fixed remuneration		Variable	Pension	Total	Proportion of	
Executive	Financial year	Base salary	Other benefits	remuneration	expense	remuneration	fixed and variable remuneration	
Kathrine Gamborg Andreassen	2022	2711	433	1874	110	5127	63.5%/ 36.5%	
CEO	2021	2478	610	1784	112	4984	64.2%/ 35.8%	
Lars Hjarrand	2022	1910	808	463	110	3291	85.9%/ 14.1%	
CFO	2021	1814	462	447	112	2835	84.2%/ 15.8%	

Note to table above: Base Salary includes monthly salary and earned holiday pay to be paid the following year. Other Benefits includes taxable gain from exercising share options, company car/ car allowance, phone/internet and others. Variable remuneration shows earned bonus for the year, to be paid the following year.

Option-based remuneration to executive personnel in the Company

Table 2 below shows the detailed information of the options that have been granted or offered to the executive personnel. The table shows the main conditions related to the different options, including number of options, the dates of grant, vesting dates, exercise price and opening/closing holdings.

Table 2

	The main conditions of share option plans				Information regarding the reported financial year						
					Opening balance	During the year			Closing Balance		
Name and position	Specification of plan	A warded date	Vesting date	Excercise price	Share options held at the beginning of the year	Share options awarded	Share options vested	Share options excercised	Share options awarded and unvested	Share options held at the end of the year	
Kathrine Gamborg Andreassen CEO	2020 Options Program	Jun 9, 2020	1/3 on Jun 9th 2021 1/3 on Jun 9th 2022 1/3 on Jun 9th 2023	19.00	105 000	0	35 000	0	70 000	105 000	
Lars Hjarrand CFO	2019 Options Program	Dec 30, 2019	1/3 on Dec 30th 2020 1/3 on Dec 30th 2021 1/3 on Dec 30th 2022	14.46	75 000	0	25 000	50 000	0	25 000	
Lars Hjarrand CFO	2020 Options Program	Jun 9, 2020	1/3 on Jun 9th 20211/3 on Jun 9th 2022 1/3 on Jun 9th 2023	19.00	75 000	0	25 000	25 000	25 000	50 000	

# **Performance-based remuneration**

The approved remuneration guidelines for executive personnel allow for variable, performance-based remuneration up to 75% of the base salary. For CEO Kathrine Gamborg Andreassen the maximum performance-based remuneration (bonus) for 2022 was 75% of base salary. For CFO Lars Hjarrand, the corresponding percentage was 25%.

75% of the bonus to the executive personnel is based on the achievements of financial targets (Revenues growth, GM% and EBITDA), while 25% is based on discretionary assessment of individual KPIs. Table 3 below shows the breakdown of the different criteria and respective achievement of each.

Table 3

CEO Kathrine G Andreassen		Potential		
	Share of bonus	Bonus	Achieved %	Awarded
Criteria A:				
Financial targets: Revenues growth, GM% and EBITDA	75 %	1 405	100 %	1 405
Criteria B:				
Successfully build pipeline to secure future revenues growth	25 %	468	100 %	468
Total	100 %	1 874	100 %	1 874

CFO Lars Hjarrand		Potential		
	Share of bonus	Bonus	Achieved %	Awarded
Criteria A				
Financial targets: Revenues growth, GM% and EBITDA	75 %	347	100 %	347
Criteria B				
Successful implementation of ERP system; including improved business cont	25 %	116	100 %	116
Total	100 %	463	100 %	463

## Total remuneration compared to the Guidelines

A prerequisite for a successful implementation of the Company's business strategy and securing the Company's long-term interests, including sustainability, is that the Company is able to recruit and retain qualified personnel. To achieve this, it is necessary for the Company to offer competitive remuneration.

The Company's remuneration guidelines enable the Company to offer leading personnel a competitive total remuneration. Total remuneration to leading personnel during 2021 complies with the Company's guidelines for remuneration. Further, the Company firmly believes that both the total remuneration, including the fixed-, variable- and option program serves to contribute to the long-term results of Navamedic.

# <u>Derogations and deviations from the remuneration guidelines and from the procedure for implementation of the guidelines</u>

In 2022, there were no deviations from the adopted remuneration guidelines.

# The company's use of access to recover variable remuneration

There were no instances in 2022 where it was deemed necessary to request a recovery of any part of the leading personnel's received remuneration or other benefits.

# Information on changes in remuneration and the Company's performance over the last 5 years

<u>Table 4</u> below shows the change in remuneration (base salary) over the past five financial years.

	2018	2019	2020	2021	2022			
Kathrine Gamborg Andreassen, CEO	N/A	1898	2 270	2 478	2 711			
Change %	N/A	N/A	20 %	9 %	9 %			
Lars Hjarrand, CFO	N/A	1700	1730	1814	1910			
Change %	N/A	N/A	2%	5 %	5 %			
Company's performance								
Revenues growth	N/A	3 %	11%	33 %	37 %			
Gross Margin %	N/A	30.5%	33.5%	40.1%	42.8%			
EBITDA	N/A	-6.5M	-1.3M	18.2M	51.7M			
Average remuneration on an FTE-basis of employees								
Change %	N/A	N/A	3.7%	3.4%	3.7%			

Notes to table 4: The table above shows base salary development. Base salary includes monthly salary and holiday pay. Kathrine Gamborg Andreassen was appointed CEO starting Jan 1, 2019. Lars Hjarrand was hired as CFO starting in December 2019. Prior to 2019 none of the current executive personnel were employed in the Company. The average change % shows the change in base salary for all non-executive personnel in the group. 2019 annualized salary for Lars Hjarrand.

# Consideration at general meeting.

This report was resolved by the Company's board of directors on 10 May and was subsequently submitted for final approval by the Company's annual general meeting on 1 June 2023.



Statsautoriserte revisorer Ernst & Young AS

Dronning Eufemias gate 6a, 0191 Oslo Postboks 1156 Sentrum, 0107 Oslo Foretaksregisteret: NO 976 389 387 MVA Tlf: +47 24 00 24 00

www.ey.no Medlemmer av Den norske Revisorforening

#### INDEPENDENT AUDITOR'S ASSURANCE REPORT ON REMUNERATION REPORT

To the General Meeting of Navamedic ASA

#### Opinion

We have performed an assurance engagement to obtain reasonable assurance that Navamedic ASA's report on salary and other remuneration to directors (the remuneration report) for the financial year ended 31 December 2022 has been prepared in accordance with section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation.

In our opinion, the remuneration report has been prepared, in all material respects, in accordance with section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation.

# Board of directors' responsibilities

The board of directors is responsible for the preparation of the remuneration report and that it contains the information required in section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation and for such internal control as the board of directors determines is necessary for the preparation of a remuneration report that is free from material misstatements, whether due to fraud or error.

## Our independence and quality control

We are independent of the company in accordance with the requirements of the relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. Our firm applies International Standard on Quality Control 1 (ISQC 1) and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

## Auditor's responsibilities

Our responsibility is to express an opinion on whether the remuneration report contains the information required in section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation and that the information in the remuneration report is free from material misstatements. We conducted our work in accordance with the International Standard for Assurance Engagements (ISAE) 3000 – "Assurance engagements other than audits or reviews of historical financial information".

We obtained an understanding of the remuneration policy approved by the general meeting. Our procedures included obtaining an understanding of the internal control relevant to the preparation of the remuneration report in order to design procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Further we performed procedures to ensure completeness and accuracy of the information provided in the remuneration report, including whether it contains the information required by the law and accompanying regulation. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Oslo, 11 May 2023 ERNST & YOUNG AS

The auditor's assurance report is signed electronically

Anja Maan State Authorised Public Accountant (Norway)

# PENN30

Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo $^{\text{TM}}$ - sikker digital signatur". De signerende parter sin identitet er registrert, og er listet nedenfor.

"Med min signatur bekrefter jeg alle datoer og innholdet i dette dokument."

Anja Maan

Oppdragsansvarlig partner
På vegne av: Ernst & Young AS
Serienummer: 9578-5997-4-370042
IP: 213.52.xxx.xxx
2023-05-11 09:03:36 UTC



# Anja Maan

Statsautorisert revisor
På vegne av: Ernst & Young AS
Serienummer: 9578-5997-4-370042
IP: 213.52.xxx.xxx
2023-05-11 09:03:36 UTC





Dokumentet er signert digitalt, med **Penneo.com**. Alle digitale signatur-data i dokumentet er sikret og validert av den datamaskin-utregnede hash-verdien av det opprinnelige dokument. Dokumentet er låst og tids-stemplet med et sertifikat fra en betrodd tredjepart. All kryptografisk bevis er integrert i denne PDF, for fremtidig validering (hvis nødvendig).

Hvordan bekrefter at dette dokumentet er orginalen?

Dokumentet er beskyttet av ett Adobe CDS sertifikat. Når du åpner dokumentet i

Adobe Reader, skal du kunne se at dokumentet er sertifisert av **Penneo e-signature service <penneo@penneo.com>**. Dette garanterer at innholdet i dokumentet ikke har blitt endret.

Pen

dokumentet ikke har blitt endret.

Det er lett å kontrollere de kryptografiske beviser som er lokalisert inne i

dokumentet, med Penneo validator - https://penneo.com/validator